Ser9
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser9  -  GSK3B (human)

Site Information
SGRPRttsFAEsCkP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 449111

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 451 , 471 ) , electrophoretic mobility shift ( 460 ) , flow cytometry ( 6 , 25 , 109 ) , immunoprecipitation ( 6 , 9 , 13 , 15 , 19 , 25 , 29 , 35 , 210 , 240 , 295 , 318 , 351 , 452 ) , mass spectrometry ( 5 , 13 , 16 , 19 , 32 , 33 , 40 , 48 , 49 , 53 , 55 , 56 , 58 , 60 , 61 , 64 , 66 , 67 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 98 , 99 , 100 , 103 , 104 , 105 , 106 , 107 , 108 , 118 , 119 , 123 , 124 , 125 , 126 , 127 , 128 , 129 , 130 , 131 , 132 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 155 , 156 , 157 , 158 , 159 , 160 , 161 , 162 , 163 , 164 , 165 , 166 , 167 , 168 , 170 , 171 , 172 , 173 , 174 , 175 , 176 , 177 , 178 , 179 , 180 , 181 , 182 , 183 , 184 , 185 , 186 , 187 , 188 , 189 , 190 , 191 , 192 , 193 , 194 , 195 , 196 , 197 , 199 , 200 , 201 , 202 , 203 , 204 , 205 , 206 , 207 , 208 , 211 , 212 , 213 , 214 , 215 , 216 , 217 , 218 , 219 , 220 , 221 , 222 , 223 , 224 , 225 , 229 , 231 , 232 , 238 , 248 , 249 , 250 , 251 , 252 , 253 , 255 , 256 , 257 , 258 , 259 , 260 , 261 , 262 , 263 , 264 , 265 , 266 , 267 , 269 , 270 , 271 , 272 , 273 , 274 , 275 , 276 , 277 , 278 , 279 , 280 , 281 , 282 , 283 , 284 , 285 , 286 , 287 , 288 , 289 , 290 , 291 , 293 , 296 , 297 , 298 , 299 , 300 , 301 , 302 , 303 , 305 , 306 , 307 , 308 , 309 , 310 , 311 , 312 , 315 , 320 , 321 , 322 , 323 , 324 , 325 , 326 , 327 , 329 , 330 , 331 , 332 , 333 , 334 , 335 , 336 , 337 , 341 , 342 , 343 , 344 , 346 , 347 , 349 , 355 , 356 , 369 ) , microscopy-colocalization with upstream kinase ( 350 , 399 ) , modification-specific antibody ( 13 , 37 ) , mutation of modification site ( 6 , 12 , 13 , 17 , 25 , 29 , 33 , 44 , 52 , 109 , 113 , 137 , 209 , 239 , 317 , 360 , 367 , 370 , 408 , 435 , 447 , 471 ) , peptide sequencing ( 43 , 228 ) , phospho-antibody ( 4 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 27 , 28 , 29 , 30 , 31 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 41 , 42 , 44 , 45 , 47 , 51 , 52 , 54 , 59 , 63 , 65 , 68 , 69 , 86 , 96 , 97 , 101 , 102 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 120 , 121 , 122 , 133 , 134 , 135 , 136 , 137 , 138 , 169 , 198 , 209 , 210 , 226 , 227 , 230 , 233 , 234 , 235 , 236 , 237 , 239 , 240 , 241 , 242 , 243 , 244 , 245 , 246 , 247 , 254 , 268 , 292 , 295 , 304 , 313 , 316 , 317 , 318 , 319 , 328 , 338 , 339 , 340 , 345 , 348 , 349 , 350 , 351 , 353 , 354 , 357 , 358 , 359 , 360 , 361 , 362 , 363 , 364 , 365 , 366 , 367 , 368 , 370 , 371 , 373 , 374 , 375 , 376 , 377 , 378 , 379 , 380 , 381 , 382 , 383 , 385 , 386 , 387 , 388 , 389 , 390 , 391 , 392 , 393 , 394 , 395 , 396 , 397 , 398 , 399 , 400 , 401 , 402 , 403 , 404 , 405 , 406 , 407 , 408 , 409 , 410 , 411 , 412 , 414 , 416 , 417 , 418 , 419 , 420 , 421 , 422 , 424 , 425 , 426 , 427 , 428 , 429 , 430 , 431 , 432 , 433 , 434 , 435 , 436 , 437 , 438 , 439 , 440 , 441 , 442 , 444 , 445 , 446 , 447 , 449 , 450 , 451 , 452 , 453 , 454 , 455 , 457 , 458 , 459 , 460 , 461 , 462 , 464 , 465 , 466 , 467 , 468 , 469 , 472 ) , phosphoamino acid analysis ( 88 ) , phosphopeptide mapping ( 471 ) , western blotting ( 4 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 27 , 28 , 29 , 30 , 31 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 41 , 42 , 44 , 45 , 47 , 51 , 52 , 54 , 59 , 63 , 65 , 69 , 86 , 88 , 96 , 97 , 101 , 102 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 120 , 121 , 122 , 133 , 134 , 135 , 136 , 137 , 138 , 169 , 198 , 209 , 210 , 226 , 227 , 228 , 230 , 233 , 234 , 235 , 236 , 237 , 239 , 240 , 241 , 242 , 243 , 244 , 245 , 246 , 247 , 268 , 292 , 295 , 304 , 313 , 316 , 317 , 318 , 319 , 328 , 338 , 339 , 340 , 345 , 348 , 349 , 350 , 351 , 353 , 354 , 357 , 358 , 359 , 360 , 361 , 362 , 363 , 364 , 365 , 367 , 368 , 370 , 371 , 373 , 374 , 375 , 376 , 377 , 378 , 379 , 380 , 381 , 382 , 383 , 385 , 387 , 388 , 389 , 390 , 391 , 393 , 395 , 398 , 399 , 406 , 407 , 409 , 414 , 416 , 417 , 418 , 424 , 425 , 426 , 427 , 428 , 429 , 431 , 434 , 435 , 437 , 438 , 439 , 440 , 441 , 445 , 446 , 447 , 449 , 452 , 453 , 454 , 455 , 457 , 458 , 461 , 464 , 468 , 469 , 472 )
Disease tissue studied:
bipolar disprder ( 11 ) , adrenal cancer ( 19 , 393 , 424 ) , pheochromocytoma ( 19 , 393 , 424 ) , bone cancer ( 21 , 227 , 233 , 360 ) , brain cancer ( 117 , 226 , 233 , 234 , 345 , 358 , 376 , 388 , 398 , 472 ) , glioblastoma ( 117 , 233 , 345 , 376 , 388 , 398 ) , glioblastoma multiforme ( 226 , 388 ) , glioma ( 117 , 226 , 233 , 345 , 376 , 388 , 398 ) , medulloblastoma ( 234 ) , Schwannoma ( 472 ) , breast cancer ( 13 , 17 , 30 , 56 , 58 , 133 , 210 , 227 , 228 , 233 , 316 , 350 , 367 , 377 , 386 , 407 , 409 , 418 , 421 , 434 , 449 , 453 ) , breast adenocarcinoma ( 227 ) , HER2 positive breast cancer ( 16 ) , luminal A breast cancer ( 16 ) , luminal B breast cancer ( 16 ) , breast cancer, surrounding tissue ( 16 ) , breast cancer, triple negative ( 16 ) , colorectal cancer ( 6 , 20 , 21 , 63 , 278 , 338 , 349 , 369 , 417 ) , colorectal carcinoma ( 6 , 20 , 21 , 63 , 338 , 349 , 369 , 417 ) , endometrial cancer ( 7 , 243 ) , endometrial adenocarcinoma ( 7 , 243 ) , gastric cancer ( 104 , 105 , 106 , 107 , 108 , 118 , 119 , 238 , 239 , 295 , 353 , 359 ) , gastric carcinoma ( 104 , 105 , 106 , 107 , 108 , 118 , 119 , 238 , 239 , 295 , 353 , 359 ) , gestational cancer ( 134 ) , gestational trophoblastic choriocarcinoma ( 134 ) , kidney cancer ( 52 ) , leukemia ( 15 , 69 , 115 , 193 , 194 , 195 , 196 , 197 , 236 , 240 , 361 , 386 ) , acute myelogenous leukemia ( 240 , 361 , 386 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 240 , 386 ) , chronic myelogenous leukemia ( 10 , 193 , 194 , 195 , 196 , 197 , 236 ) , T cell leukemia ( 69 , 115 ) , liver cancer ( 4 , 23 , 28 , 114 , 377 , 379 , 440 ) , liver adenocarcinoma ( 28 ) , hepatocellular carcinoma ( 4 ) , lung cancer ( 4 , 50 , 96 , 123 , 124 , 125 , 126 , 127 , 128 , 129 , 130 , 131 , 132 , 211 , 233 , 238 , 254 , 266 , 338 , 367 , 369 , 429 ) , mesothelioma ( 125 ) , non-small cell lung cancer ( 4 , 50 , 96 , 123 , 124 , 125 , 126 , 127 , 128 , 129 , 130 , 131 , 132 , 211 , 254 , 338 , 367 ) , non-small cell lung adenocarcinoma ( 4 , 50 , 123 , 126 , 127 , 128 , 129 , 130 , 131 , 238 ) , non-small cell large cell lung carcinoma ( 96 ) , non-small cell squamous cell lung carcinoma ( 124 , 125 , 132 , 238 , 266 , 338 ) , lymphoma ( 12 , 41 , 69 , 237 , 240 , 313 , 381 , 386 ) , B cell lymphoma ( 12 , 69 , 381 ) , Burkitt's lymphoma ( 381 ) , non-Hodgkin's lymphoma ( 12 , 69 ) , mantle cell lymphoma ( 12 , 69 ) , PEL ( 41 ) , neuroblastoma ( 8 , 19 , 27 , 31 , 32 , 55 , 110 , 116 , 122 , 138 , 203 , 204 , 205 , 206 , 207 , 318 , 354 , 358 , 378 , 424 , 439 , 445 , 457 ) , ovarian cancer ( 20 , 21 , 423 , 449 ) , pancreatic cancer ( 18 , 21 , 26 , 113 , 210 , 406 , 414 ) , pancreatic carcinoma ( 18 , 21 , 26 , 210 , 406 , 414 ) , pancreatic ductal adenocarcinoma ( 48 ) , prostate cancer ( 34 , 35 , 241 , 267 , 339 , 382 , 416 , 428 , 468 ) , melanoma skin cancer ( 9 , 242 , 389 ) , fibrosarcoma of soft tissue ( 458 ) , thyroid cancer ( 383 ) , schizophrenia ( 431 ) , sporadic inclusion-body myositis ( 44 , 235 )
Relevant cell line - cell type - tissue:
'brain, cerebellum' ( 234 ) , 'brain, cerebral cortex' ( 24 , 427 , 431 ) , 'brain, cerebral cortex' [Akt3 (mouse), no information] ( 45 ) , 'brain, hippocampus' ( 11 , 396 ) , 'brain, striatum' ( 396 ) , 'macrophage, alveolar'-lung ( 465 ) , 'muscle, skeletal' ( 47 , 121 , 135 , 235 , 340 , 348 , 394 , 400 ) , 'muscle, smooth'-'heart, artery' ( 209 ) , 'neuron, cerebellar granule'-brain ( 403 ) , 'neuron, cortical'-brain ( 396 ) , 'neuron, dorsal root ganglion'-brain ( 453 ) , 'neuron, hippocampal'-brain ( 396 ) , 'pancreatic, ductal'-pancreas ( 48 ) , 'stem, embryonic' ( 65 ) , 'stem, induced pluripotent' ( 11 , 68 ) , 21T (breast cell) ( 210 ) , 22Rv1 (prostate cell) ( 425 ) , 293 (epithelial) ( 4 , 6 , 25 , 29 , 33 , 51 , 71 , 72 , 73 , 74 , 75 , 137 , 233 , 364 , 370 , 375 , 380 , 381 , 385 , 393 , 412 , 421 , 428 , 432 , 433 , 441 , 452 , 464 , 467 , 469 ) , 293E (epithelial) ( 86 ) , 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 402 , 430 , 467 ) , 3T3 (fibroblast) ( 33 , 390 ) , 786-O (renal) ( 52 ) , A172 (glial) ( 404 ) , A2780 (ovarian) ( 21 ) , A375 (melanocyte) ( 242 ) , A549 (pulmonary) ( 4 , 50 , 233 , 338 , 369 , 429 ) , A7r5 ('muscle, smooth') ( 209 ) , ACN ( 27 ) , agranulocyte-blood ( 371 ) , AGS (gastric) [CCKBR (human), transfection] ( 239 ) , AGS (gastric) ( 295 , 359 ) , Aspc1 (pancreatic) ( 18 , 21 , 26 ) , B lymphocyte ( 381 ) , BAEC (endothelial) ( 368 ) , BC3 (B lymphocyte) ( 41 ) , Ben-Men-1 ( 472 ) , BeWo31 ( 268 ) , BeWo ( 268 ) , BJAB (B lymphocyte) ( 381 ) , breast ( 13 , 16 ) , BT-20 (breast cell) ( 58 ) , BT-474 (breast cell) ( 367 , 409 ) , BT-549 (breast cell) ( 58 ) , C4-2 (prostate cell) ( 241 , 425 ) , Calu-1 (squamous) ( 96 ) , Calu-3 (pulmonary) ( 131 ) , CFPAC-1 (pancreatic) ( 365 ) , CHO (fibroblast) [EphB1 (human), transfection] ( 469 ) , CHO (fibroblast) [EPOR (human)] ( 370 ) , CHO (fibroblast) ( 439 ) , chromaffin-adrenal gland ( 304 ) , colon ( 278 ) , COS (fibroblast) ( 373 , 385 , 395 , 399 , 446 , 453 ) , COS7 (fibroblast) ( 135 ) , Daoy ( 234 ) , dendritic cell ( 109 ) , DM4 (melanocyte) ( 242 ) , DU 145 (prostate cell) ( 35 , 339 , 425 , 468 ) , DV-90 (pulmonary) ( 129 ) , endothelial-aorta ( 391 ) , endothelial-vein ( 447 ) , epithelial-lens ( 169 ) , erythroblast-spleen ( 459 ) , ES (stem) ( 393 ) , fibroblast-foreskin ( 429 ) , FTC-133 (thyroid cell) ( 411 ) , GI-101A (breast cell) ( 449 ) , GRANTA-519 (B lymphocyte) ( 12 ) , H19-7 (neuron) [IGF1R (human)] ( 404 ) , HaCaT (keratinocyte) ( 438 , 462 ) , HCC1937 (breast cell) ( 58 ) , HCEC (epithelial) ( 247 ) , HCN-2 ('neuron, cortical') ( 246 ) , HCT116 (intestinal) ( 6 , 20 , 63 , 258 , 338 , 349 , 369 , 417 ) , heart ( 135 , 227 ) , HEI-193 (Schwann) ( 472 ) , HEK293T (epithelial) ( 44 , 135 , 210 , 244 , 317 , 351 , 367 , 408 , 409 , 436 , 454 ) , HeLa (cervical) ( 13 , 40 , 42 , 50 , 59 , 111 , 135 , 230 , 245 , 248 , 249 , 250 , 251 , 252 , 253 , 291 , 347 , 365 , 370 , 379 , 444 ) , HeLa S3 (cervical) ( 346 , 471 ) , HeLa_Meta (cervical) ( 208 ) , HeLa_Pro (cervical) ( 208 ) , HeLa_Telo (cervical) ( 208 ) , Hep 3B2.1-7 (hepatic) ( 401 ) , hepatocyte-liver ( 4 , 292 ) , HepG2 (hepatic) ( 4 , 23 , 114 , 257 , 377 , 379 , 401 , 419 , 440 , 450 ) , HEY (ovarian) ( 449 ) , HL60 (myeloid) ( 15 , 240 ) , HMVEC (endothelial) ( 39 ) , HN5 (squamous) ( 410 ) , Hs 578T (breast cell) ( 367 ) , HS294T (melanocyte) ( 242 ) , HT-29 (intestinal) ( 408 ) , HT1080 (fibroblast) ( 430 , 466 ) , Huh7 (hepatic) ( 4 ) , HUVEC (endothelial) ( 328 , 374 , 429 , 455 ) , IGROV1 (ovarian) ( 442 ) , IMR-90 (fibroblast) ( 113 ) , IOSE-29 (ovarian) ( 442 ) , Ishikawa (endometrial) ( 243 ) , JAR (placental) ( 136 ) , JB (epithelial) ( 426 ) , JEG-3 (uterine) ( 134 ) , JEKO-1 (B lymphocyte) ( 12 , 69 ) , Jurkat (T lymphocyte) ( 49 , 64 , 66 , 67 , 69 , 80 , 81 , 82 , 83 , 84 , 85 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 98 , 99 , 100 , 102 , 103 , 115 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 155 , 156 , 157 , 158 , 159 , 160 , 161 , 162 , 163 , 164 , 165 , 166 , 167 , 168 , 170 , 171 , 172 , 173 , 174 , 175 , 176 , 177 , 178 , 179 , 180 , 181 , 182 , 183 , 184 , 185 , 186 , 187 , 188 , 189 , 190 , 191 , 192 , 199 , 200 , 201 , 202 , 212 , 213 , 214 , 215 , 216 , 217 , 218 , 219 , 220 , 221 , 222 , 223 , 224 , 225 , 229 , 231 , 232 , 259 , 260 , 261 , 262 , 263 , 264 , 265 , 269 , 270 , 271 , 272 , 273 , 274 , 275 , 276 , 277 , 279 , 280 , 281 , 282 , 283 , 284 , 285 , 286 , 287 , 288 , 289 , 293 , 296 , 297 , 298 , 299 , 300 , 301 , 302 , 303 , 315 , 355 , 356 , 369 , 405 , 420 ) , K562 (erythroid) ( 53 , 193 , 194 , 195 , 196 , 197 , 236 ) , KG-1 (myeloid) ( 240 , 386 ) , KLE (endometrial) ( 7 ) , L02 (hepatic) ( 38 , 88 ) , L6 (myoblast) ( 47 , 400 ) , LAN-1 (neural crest) ( 318 ) , LAN-6 (neural crest) ( 32 , 203 , 204 ) , LAPC-4 (prostate cell) ( 425 ) , liver ( 135 , 292 ) , LN-Z308 (glial) ( 376 ) , LN229 (glial) ( 388 ) , LNCaP (prostate cell) ( 34 , 35 , 267 , 382 , 425 , 428 , 468 ) , LOU-NH91 (squamous) ( 124 ) , lung ( 43 , 227 , 266 ) , lymph node ( 237 ) , lymphocyte ( 431 ) , lymphocyte-blood ( 10 ) , M14-MEL (melanocyte) ( 9 , 389 ) , macrophage-bone marrow ( 14 , 109 ) , MC3T3 (preosteoblast) ( 451 ) , MCF-10A (breast cell) ( 30 , 449 ) , MCF-7 (breast cell) [CYP19A1 (human)] ( 407 ) , MCF-7 (breast cell) ( 17 , 58 , 233 , 316 , 365 , 367 , 377 , 386 , 418 , 421 ) , MCF12A (epithelial) ( 13 ) , MDA-MB-231 (breast cell) ( 13 , 58 , 316 , 367 , 418 , 453 ) , MDA-MB-361 (breast cell) ( 227 ) , MDA-MB-435 (breast cell) ( 133 , 365 ) , MDA-MB-453 (breast cell) ( 365 ) , MDA-MB-468 (breast cell) ( 58 , 228 ) , MDAH2774 (ovarian) ( 365 ) , MEF (fibroblast) ( 20 , 44 , 109 , 135 , 360 ) , MEF (fibroblast) [Akt1 (mouse), homozygous knockout] ( 97 ) , MEF (fibroblast) [Etk (human), heterozygous knockout] ( 54 ) , MEF (fibroblast) [Myc (mouse)] ( 389 ) , MEL624 (melanocyte) ( 242 ) , mesangial ( 120 ) , MeWo (melanocyte) ( 242 ) , microvessel endothelial ( 198 , 319 ) , MKN-45 (gastric) ( 104 , 105 , 106 , 107 , 108 , 118 , 119 , 238 , 333 , 334 , 335 , 336 , 337 , 341 , 342 , 359 ) , MKN-74 (gastric) ( 295 ) , monocyte-blood ( 109 ) , MSN (neuron) ( 422 ) , muscle ( 44 ) , MV4-11 (macrophage) ( 258 ) , myoblast ( 366 ) , NA (squamous) ( 397 ) , NB-4 (myeloid) ( 386 ) , NB10 (neural crest) ( 55 ) , NCI-H1299 (pulmonary) ( 338 ) , NCI-H157 (pulmonary) ( 96 , 367 , 408 ) , NCI-H1650 (pulmonary) ( 128 , 211 , 338 ) , NCI-H1703 (squamous) ( 238 , 305 , 306 , 307 , 308 , 309 , 310 , 311 , 312 , 329 , 330 , 331 , 332 , 338 , 343 , 344 ) , NCI-H1792 (pulmonary) ( 96 ) , NCI-H1975 (pulmonary) ( 127 ) , NCI-H2073 (pulmonary) ( 123 ) , NCI-H2170 (squamous) ( 132 ) , NCI-H226 (pulmonary) ( 125 ) , NCI-H23 (pulmonary) ( 338 ) , NCI-H2342 (pulmonary) ( 130 ) , NCI-H3255 (pulmonary) ( 238 , 255 , 256 , 320 , 321 , 322 , 323 , 324 , 325 , 326 , 327 ) , NCI-H358 (pulmonary) ( 96 ) , NCI-H441 (pulmonary) ( 126 ) , NCI-H460 (pulmonary) ( 96 , 254 , 338 ) , neuron-'brain, cerebellum' ( 424 ) , neuron-'brain, hippocampus' ( 445 ) , neutrophil ( 461 ) , NPC (neural crest) ( 55 ) , OK (renal) ( 363 ) , ovary ( 423 ) , OVCAR3 (ovarian) ( 365 ) , OVCAR4 (ovarian) ( 423 ) , OVCAR5 (ovarian) ( 423 ) , PANC-1 (pancreatic) ( 18 , 210 , 406 ) , pancreas ( 18 , 414 ) , pancreatic ( 113 ) , PC-12 (chromaffin) ( 19 , 393 , 404 , 424 ) , PC3 (prostate cell) ( 34 , 35 , 241 , 339 , 416 , 425 , 435 , 468 ) , QZG (hepatic) ( 88 ) , Raji (B lymphocyte) ( 381 ) , Rat1 (fibroblast) ( 467 ) , RAW 264.7 (macrophage) ( 4 ) , Saos-2 (bone cell) ( 451 ) , SB2 (melanocyte) ( 242 ) , Schwann ( 317 ) , SH-SY5Y (neural crest) ( 8 , 19 , 31 , 32 , 110 , 116 , 138 , 206 , 207 , 354 , 378 , 392 , 404 , 424 , 433 , 445 , 457 , 460 ) , SHEP (neuron) ( 422 ) , SK-HEP-1 (endothelial) ( 28 ) , SK-MEL2 (melanocyte) ( 242 ) , SK-MEL28 (melanocyte) ( 22 ) , SK-MEL5 (melanocyte) ( 242 ) , SK-N-BE(2) (neural crest) ( 8 , 32 ) , SK-N-MC (neural crest) ( 122 , 422 ) , SKBr3 (breast cell) ( 56 , 350 , 365 , 367 , 434 ) , skin ( 242 ) , SKNSH (neural crest) ( 19 , 439 ) , SKOV-3 (ovarian) ( 20 , 423 , 442 ) , SMMC7721 (hepatocyte) ( 28 ) , SMS-KCN-A (neural crest) ( 32 , 205 ) , SNB-19 (glial) ( 388 , 398 ) , SNU-1 (gastric) ( 359 ) , SNU-484 (gastric) ( 353 ) , SNU-620 (gastric) ( 353 ) , SNU16Ad (gastric) ( 295 ) , spermatozoa ( 37 ) , Su.86.86 (pancreatic) ( 18 ) , SUM159 (breast cell) ( 17 ) , SW480 (intestinal) ( 6 ) , SW620 (intestinal) ( 21 ) , Swiss 3T3 (fibroblast) ( 454 ) , synoviocyte-synovium ( 357 ) , T lymphocyte ( 101 ) , T lymphocyte-blood ( 61 , 112 , 357 ) , T47D (breast cell) ( 350 , 365 ) , TF-1 (erythroid) ( 386 ) , THP1 (myeloid) ( 361 ) , thymocyte ( 351 ) , TT (thyroid cell) ( 383 ) , U-251 MG (glial) ( 345 , 376 , 388 , 398 ) , U-937 (myeloid) ( 240 , 313 , 386 ) , U2OS (bone cell) ( 21 , 227 , 233 , 360 ) , U373 MG (glial) ( 226 , 388 ) , U87MG (glial) ( 117 , 233 , 388 , 398 ) , UACC-257 (melanocyte) ( 242 ) , UCSD-354L (melanocyte) ( 242 ) , vascular smooth muscle cell ('muscle, smooth') ( 362 ) , WEHI-164 (fibroblast) ( 458 ) , WEHI-231 (B lymphocyte) ( 381 ) , WI-38 (fibroblast) ( 430 ) , WM-1552 (melanocyte) ( 242 ) , WM115 (melanocyte) ( 290 ) , WM1799 (melanocyte) ( 242 ) , WM2664 (melanocyte) ( 242 ) , WM3211 (melanocyte) ( 242 ) , WM35 (melanocyte) ( 242 ) , WM46 (melanocyte) ( 242 ) , ZR-75-1 (breast cell) ( 367 , 377 )

Upstream Regulation
Regulatory protein:
Akt1 (cow) ( 448 ) , Akt1 (human) ( 65 , 113 , 363 , 367 , 374 , 417 ) , Akt2 (human) ( 367 ) , Akt3 (human) ( 45 , 367 ) , AurA (human) ( 295 ) , BAP28 (human) ( 18 ) , BRAF (human) ( 242 ) , CHKA (human) ( 316 ) , CHKB (human) ( 316 ) , CYR61 (human) ( 226 ) , DARPP-32 (human) ( 359 ) , DDIT4 (human) ( 412 ) , DDIT4L (human) ( 412 ) , Diaphanous-1 (mouse) ( 373 ) , Diaphanous-2 (mouse) ( 373 ) , DKK1 (human) ( 120 ) , E4 (adenovirus) ( 429 ) , EDG4 (human) ( 454 ) , EDG7 (human) ( 454 ) , FKBP5 (human) ( 7 ) , FSTL1 (mouse) ( 328 ) , GRP78 (human) ( 134 ) , GSK3B (human) ( 35 , 365 ) , HRas (human) ( 113 ) , IEX-1 (human) ( 370 ) , IKKB (human) ( 348 ) , IKKE (human) ( 57 ) , ILK (human) ( 406 , 428 , 441 , 468 ) , ILKAP (human) ( 428 , 464 ) , IRAK4 (human) ( 57 ) , ITGB1 (mouse) ( 294 ) , KIF1B (human) ( 19 ) , LAPTM4B (human) ( 34 ) , LKB1 (human) ( 338 ) , Lmr2 (human) ( 59 ) , LPAR1 (human) ( 454 ) , LPIN1 (mouse) ( 292 ) , LRPAP1 (human) ( 313 ) , MEK1 (human) ( 65 , 363 ) , Merlin (human) ( 17 ) , MKK3 (human) ( 351 ) , MKK6 (human) ( 351 ) , Notch 1 (human) ( 384 ) , NRas (human) ( 242 ) , OLA1 (human) ( 20 ) , OSBPL8 (mouse) ( 114 ) , p16-INK4A (human) ( 36 ) , P2X7 (human) ( 27 ) , p300 (human) ( 135 ) , p53 (human) ( 384 ) , PARVB (human) ( 418 ) , PCAF (human) ( 135 ) , PCGF2 (human) ( 350 ) , PGGT1B (mouse) ( 14 ) , PHLPP (human) ( 210 , 367 ) , PHLPP2 (human) ( 210 , 367 ) , PINK1 (human) ( 116 ) , PKCA (human) ( 243 ) , PKCE (human) ( 373 ) , PKCT (human) ( 52 ) , PPP1CA (human) ( 169 ) , PPP1R2 (human) ( 378 ) , PTEN (human) ( 468 ) , PTPRA (human) ( 51 ) , RAF1 (human) ( 65 ) , RHOA (human) ( 4 ) , RICTOR (human) ( 109 ) , RPS23 (mouse) ( 245 ) , SGK1 (human) ( 31 ) , SHIP (human) ( 112 , 420 ) , SMAD7 (human) ( 416 ) , TACC3 (human) ( 28 ) , TORC2 (mouse) ( 292 ) , TSC2 (human) ( 379 )
Putative in vivo kinases:
Akt1 (human) ( 10 , 351 , 435 ) , AurA (human) ( 295 ) , KHS1 (human) ( 381 ) , p70S6K iso2 (human) ( 109 ) , p90RSK (human) ( 401 , 471 ) , PKACA (human) ( 467 ) , PKCA (human) ( 96 , 454 ) , PKCB (human) ( 96 , 454 ) , PKCH (human) ( 454 ) , PKCZ (human) ( 25 ) , SGK3 (human) ( 452 )
Kinases, in vitro:
Akt1 (human) ( 420 , 456 , 458 , 463 , 470 ) , AurA (human) ( 295 ) , KHS1 (human) ( 381 ) , p70S6K (human) ( 470 , 471 ) , P70S6KB (human) ( 109 ) , p90RSK (human) ( 471 ) , PKACA (human) ( 467 ) , PKCA (human) ( 454 ) , PKCB iso2 (human) ( 454 ) , PKCD (human) ( 454 ) , PKCG (human) ( 454 ) , PKCH (human) ( 454 ) , RSK2 (human) ( 461 , 470 ) , SGK3 (human) ( 452 )
Putative upstream phosphatases:
laforin (human) ( 375 , 399 ) , PPP1CA (human) ( 59 , 396 ) , PPP2CA (human) ( 240 )
Phosphatases, in vitro:
laforin (human) ( 399 )
Treatments:
hyperoside ( 38 ) , 2-bromohexadecanoid_acid ( 377 ) , 2-deoxyglucose ( 254 , 446 ) , 3MCIC ( 23 ) , 4-HT ( 30 , 65 ) , 5-HT ( 209 ) , 5-thio-glucose ( 446 ) , 6-OHDA ( 31 , 424 ) , A-443654 ( 318 ) , A740003 ( 27 ) , activin ( 65 ) , adenosine ( 37 ) , AG1478 ( 116 , 404 ) , Akt-I-1 ( 230 , 361 , 363 , 413 ) , Akt-I-1,2 ( 86 ) , Akt_inhibitor_IV ( 57 ) , Akt_inhibitor_VIII ( 116 , 295 ) , amino_acid_starvation ( 42 ) , amino_acids ( 400 ) , anthrax_toxin ( 361 ) , anti-Akt1 ( 409 ) , anti-CD28 ( 101 ) , anti-CD3 ( 61 , 112 ) , anti-CTLA-4 ( 101 ) , anti-EPCR ( 313 ) , anti-FGF19 ( 349 ) , anti-ICOS ( 101 ) , anti-IgM ( 12 ) , anti-ITGA4 ( 240 ) , anti-ITGA5 ( 240 ) , anti-PAR1 ( 313 ) , AP21967 ( 448 ) , APC ( 313 ) , apocynin ( 26 ) , ARC ( 358 ) , AZ1060120 ( 27 ) , AZD8055 ( 233 ) , B7 ( 101 ) , BAPTA-AM ( 438 ) , BDNF ( 424 ) , bicalutamide ( 425 ) , BIM-23120 ( 383 ) , bisindolylmaleimide ( 373 ) , BMP4 ( 209 ) , brefeldin_A ( 445 ) , BzATP ( 27 ) , caffeine ( 117 , 426 ) , calphostin_C ( 404 ) , calyculin_A ( 371 , 445 ) , cAMP_analog ( 447 , 467 ) , canertinib ( 354 ) , CDDO-Me ( 339 ) , celecoxib ( 96 ) , cell_adhesion ( 240 ) , CHIR99021 ( 8 ) , ciclosporin ( 404 , 445 ) , colforsin ( 29 , 317 , 403 , 447 , 467 ) , collagen ( 437 ) , collagen XIX (NC1 domain) ( 22 ) , convulxin ( 437 ) , CTGF ( 120 ) , DAMGO ( 439 , 469 ) , depolarization ( 378 , 403 , 404 ) , derivative-2 ( 41 ) , EDTA ( 404 ) , eflornithine ( 318 ) , EGF ( 116 , 136 , 247 , 354 , 382 , 388 , 418 , 421 , 426 , 435 ) , endothelin ( 209 ) , englerin_A ( 52 ) , enzastaurin ( 319 , 345 , 353 ) , Epo ( 370 , 459 ) , erlotinib ( 410 ) , estradiol ( 228 , 377 ) , estren ( 377 ) , estrogen_deprivation ( 407 ) , exercise ( 394 ) , FGF19 ( 349 ) , FGF2 ( 65 ) , fibronectin ( 464 ) , fipronil ( 110 ) , FK506 ( 404 , 445 ) , fMLP ( 461 ) , gastrin ( 239 ) , gefitinib ( 238 , 434 ) , geldanamycin ( 434 ) , GF109203X ( 96 ) , ginsenoside-Rg1 ( 374 ) , glucocorticoid ( 451 ) , glucose ( 419 , 446 ) , glucose_starvation ( 380 ) , Go_6976 ( 96 ) , Go_6983 ( 96 ) , H-7 ( 461 ) , H-89 ( 117 , 403 , 404 , 413 , 447 , 461 , 467 ) , H2O2 ( 389 , 466 ) , HA-1004 ( 461 ) , HA1077 ( 8 ) , HB-EGF ( 136 ) , heat_shock ( 457 ) , heregulin ( 65 ) , HGF ( 50 , 226 , 352 ) , homocysteine ( 37 ) , hypoxia ( 268 , 440 , 446 , 466 ) , IBMX ( 29 ) , idelalisib ( 12 ) , IGF-1 ( 65 , 365 , 403 , 410 , 413 , 421 , 433 , 435 , 445 , 467 ) , IL-1a ( 57 ) , IL-1b ( 198 ) , imatinib ( 238 ) , insulin ( 25 , 47 , 57 , 86 , 114 , 121 , 292 , 294 , 304 , 340 , 348 , 366 , 373 , 375 , 379 , 400 , 419 , 435 , 436 , 439 , 450 ) , ionizing_radiation ( 319 , 417 ) , ionomycin ( 102 ) , IP(6) ( 241 ) , IQA ( 405 ) , isoproterenol ( 467 ) , kenpaullone ( 110 , 345 ) , KHS101 ( 28 ) , KN-62 ( 403 , 404 ) , KN-92 ( 411 ) , KN-93 ( 411 ) , KP-372-1 ( 386 , 388 ) , KP-372-2 ( 388 ) , laminar flow ( 368 ) , leucine ( 42 ) , leucine_deprivation ( 42 ) , linoleic_acid ( 47 ) , lithium ( 11 , 88 , 110 , 209 , 235 , 245 , 339 , 345 , 365 , 371 , 374 , 390 , 403 , 411 , 440 , 453 ) , low_Ca(2+) ( 404 ) , low_glucose ( 135 ) , low_K(+) ( 403 ) , LPA ( 373 , 449 , 454 , 467 ) , LPS ( 14 , 109 , 415 , 465 ) , LTD4 ( 387 ) , LY2064827 ( 345 ) , LY294002 ( 4 , 21 , 65 , 88 , 96 , 230 , 246 , 247 , 313 , 316 , 318 , 361 , 365 , 374 , 376 , 377 , 382 , 387 , 404 , 405 , 413 , 416 , 425 , 433 , 435 , 437 , 440 , 446 , 447 , 449 , 453 , 455 , 457 , 461 , 465 , 467 ) , lysine ( 42 ) , lysine_deprivation ( 42 ) , mechanical stress ( 198 ) , metribolone ( 425 ) , MG132 ( 421 ) , mifepristone ( 374 ) , miRNA ( 34 ) , ML-9 ( 403 ) , morphine ( 439 ) , NAC ( 424 ) , naloxone ( 469 ) , nifedipine ( 404 ) , okadaic_acid ( 37 , 240 , 404 , 424 , 445 ) , oleic_acid ( 47 ) , oscillatory_flow ( 368 ) , OSI-027 ( 69 ) , OSU-T315 ( 472 ) , ouabain ( 363 ) , PAO ( 371 ) , PD98059 ( 365 , 374 , 392 , 404 , 421 , 447 , 449 , 461 ) , PDGF ( 426 ) , PF-4708671 ( 109 ) , phorbol_ester ( 102 , 371 , 372 ) , PI(3,4)P2 ( 317 ) , PI-103 ( 116 ) , PKI-402 ( 227 ) , PLTP ( 246 ) , poly-L-lysine ( 464 ) , putrescine ( 318 ) , QLT0254 ( 414 ) , QLT0267 ( 398 ) , racepinefrine ( 121 ) , rapamycin ( 69 , 96 , 109 , 113 , 362 , 379 , 404 ) , resveratrol ( 26 , 135 , 236 ) , retinoic_acid ( 15 ) , Ro31-8220 ( 96 ) , rottlerin ( 96 ) , RRD-251 ( 15 ) , S-valproate ( 352 ) , sardomozide ( 318 ) , SB203580 ( 351 , 416 , 449 ) , SB216763 ( 209 ) , SCF ( 459 ) , SCH_23390 ( 122 ) , Sem3A ( 453 ) , serum ( 376 , 382 , 426 , 447 , 451 , 455 , 460 , 468 ) , serum_starvation ( 63 , 86 ) , serum_withdrawal ( 390 , 455 , 457 ) , SH-6 ( 374 , 376 ) , siRNA ( 240 , 338 , 348 , 365 , 367 , 379 , 386 , 391 , 395 , 406 , 416 , 428 ) , SKF38393 ( 122 ) , SN-50 ( 403 ) , somatostatin ( 383 ) , spermidine ( 318 ) , spermine ( 318 ) , sphingosine_1-phosphate ( 391 , 449 ) , staurosporine ( 365 , 438 , 457 ) , Su11274 ( 238 ) , sunitinib ( 234 ) , tanespimycin ( 236 ) , tautomycetin ( 59 ) , TBB ( 405 ) , TGF-beta ( 88 , 209 , 416 ) , thapsigargin ( 133 , 424 , 430 , 438 , 445 ) , thrombin ( 437 ) , TNF ( 348 , 352 , 435 , 436 , 458 ) , Torin1 ( 86 ) , TPO ( 370 ) , TRAIL ( 443 ) , tungstate ( 392 ) , tunicamycin ( 133 , 134 , 424 , 430 , 445 ) , U0126 ( 65 , 290 , 363 , 421 ) , U71322 ( 438 ) , UCN-01 ( 422 ) , UV ( 365 ) , virus infection ( 39 ) , W-5 ( 411 ) , W-7 ( 411 ) , Wnt3a ( 25 ) , Wnt5a ( 25 ) , wortmannin ( 96 , 116 , 228 , 236 , 238 , 239 , 314 , 351 , 404 , 413 , 415 , 421 , 433 , 437 , 453 , 458 , 461 , 465 , 467 ) , Y27632 ( 4 ) , YM_022 ( 239 ) , Z-DEVD-fmk ( 339 ) , Z-IETD-fmk ( 339 ) , ZM198,615 ( 387 )

Downstream Regulation
Effects of modification on GSK3B:
activity, inhibited ( 399 , 402 , 403 , 460 ) , enzymatic activity, inhibited ( 44 , 59 , 65 , 96 , 101 , 109 , 115 , 240 , 304 , 339 , 351 , 390 , 392 , 396 , 401 , 435 , 444 , 451 , 453 , 459 , 462 , 467 , 471 ) , intracellular localization ( 435 ) , phosphorylation ( 435 ) , protein degradation ( 96 , 427 ) , ubiquitination ( 96 )
Effects of modification on biological processes:
apoptosis, altered ( 338 , 339 ) , apoptosis, induced ( 96 ) , apoptosis, inhibited ( 403 , 447 ) , carcinogenesis, induced ( 5 ) , cell adhesion, altered ( 447 ) , cell differentiation, induced ( 65 ) , cell growth, altered ( 435 ) , cell motility, altered ( 239 ) , cytoskeletal reorganization ( 447 ) , signaling pathway regulation ( 109 , 439 ) , transcription, altered ( 239 , 462 )

Disease / Diagnostics Relevance
Relevant diseases:
Alzheimer's disease ( 68 , 427 ) , bipolar disprder ( 371 ) , breast cancer ( 13 , 365 ) , lymphoma ( 237 ) , neuroblastoma ( 5 ) , ovarian cancer ( 423 ) , pancreatic cancer ( 113 ) , melanoma skin cancer ( 242 ) , type 2 diabetes ( 427 ) , Parkinson's disease ( 24 ) , schizophrenia ( 431 )

References 

1

Jungers CF, et al. (2020) Regulation of eukaryotic translation initiation factor 6 dynamics through multisite phosphorylation by GSK3. J Biol Chem
32703900   Curated Info

2

Miller WP, et al. (2020) The stress response protein REDD1 promotes diabetes-induced oxidative stress in the retina by Keap1-independent Nrf2 degradation. J Biol Chem
32295843   Curated Info

3

Fang X, et al. (2019) Isoflurane aggravates peripheral and central insulin resistance in high-fat diet/streptozocin-induced type 2 diabetic mice. Brain Res, 146511
31672472   Curated Info

4

Islam R, et al. (2018) Insulin induces phosphorylation of pyruvate dehydrogenase through RhoA activation pathway in HepG2 cells. FASEB J, fj201800917R
30226812   Curated Info

5

Braekeveldt N, et al. (2018) Patient-derived xenograft models reveal intratumor heterogeneity and temporal stability in neuroblastoma. Cancer Res
30154149   Curated Info

6

Liang J, et al. (2017) miR-27a-3p targeting RXRα promotes colorectal cancer progression by activating Wnt/β-catenin pathway. Oncotarget 8, 82991-83008
29137318   Curated Info

7

Dong J, et al. (2017) FKBP51 decreases cell proliferation and increases progestin sensitivity of human endometrial adenocarcinomas by inhibiting Akt. Oncotarget 8, 80405-80415
29113312   Curated Info

8

Dyberg C, et al. (2017) Rho-associated kinase is a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A 114, E6603-E6612
28739902   Curated Info

9

Hur EH, et al. (2017) Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells. Oncotarget 8, 41387-41400
28574827   Curated Info

10

Jin Y, et al. (2017) Gas6/AXL Signaling Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing β-Catenin. Clin Cancer Res 23, 2842-2855
27852702   Curated Info

11

Tobe BTD, et al. (2017) Probing the lithium-response pathway in hiPSCs implicates the phosphoregulatory set-point for a cytoskeletal modulator in bipolar pathogenesis. Proc Natl Acad Sci U S A 114, E4462-E4471
28500272   Curated Info

12

Yang Q, et al. (2017) Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma. Clin Cancer Res 23, 181-192
27342398   Curated Info

13

Ko HW, et al. (2016) GSK3β inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers. Oncotarget 7, 57131-57144
27494834   Curated Info

14

Akula MK, et al. (2016) Control of the innate immune response by the mevalonate pathway. Nat Immunol 17, 922-9
27270400   Curated Info

15

Wallace AS, Supnick HT, Bunaciu RP, Yen A (2016) RRD-251 enhances all-trans retinoic acid (RA)-induced differentiation of HL-60 myeloblastic leukemia cells. Oncotarget 7, 46401-46418
27331409   Curated Info

16

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

17

Morrow KA, et al. (2016) Loss of tumor suppressor Merlin results in aberrant activation of Wnt/β-catenin signaling in cancer. Oncotarget 7, 17991-8005
26908451   Curated Info

18

Liu T, et al. (2016) HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy. Cancer Res 76, 572-81
26676747   Curated Info

19

Li S, et al. (2016) The 1p36 Tumor Suppressor KIF 1Bβ Is Required for Calcineurin Activation, Controlling Mitochondrial Fission and Apoptosis. Dev Cell 36, 164-78
26812016   Curated Info

20

Xu D, et al. (2016) Obg-like ATPase 1 regulates global protein serine/threonine phosphorylation in cancer cells by suppressing the GSK3β-inhibitor 2-PP1 positive feedback loop. Oncotarget 7, 3427-39
26655089   Curated Info

21

Sakurikar N, Thompson R, Montano R, Eastman A (2016) A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase. Oncotarget 7, 1380-94
26595527   Curated Info

22

Oudart JB, et al. (2016) The anti-tumor NC1 domain of collagen XIX inhibits the FAK/ PI3K/Akt/mTOR signaling pathway through αvβ3 integrin interaction. Oncotarget 7, 1516-28
26621838   Curated Info

23

Cao L, Zhang L, Zhao X, Zhang Y (2016) A Hybrid Chalcone Combining the Trimethoxyphenyl and Isatinyl Groups Targets Multiple Oncogenic Proteins and Pathways in Hepatocellular Carcinoma Cells. PLoS One 11, e0161025
27525972   Curated Info

24

Xing H, et al. (2016) Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with β-amyloid burden and synaptic deficits in Lewy body dementias. Mol Brain 9, 84
27609071   Curated Info

25

Tejeda-Muñoz N, et al. (2015) Glycogen Synthase Kinase 3β Is Positively Regulated by Protein Kinase Cζ-Mediated Phosphorylation Induced by Wnt Agonists. Mol Cell Biol 36, 731-41
26711256   Curated Info

26

Kato A, et al. (2015) Chemopreventive effect of resveratrol and apocynin on pancreatic carcinogenesis via modulation of nuclear phosphorylated GSK3β and ERK1/2. Oncotarget 6, 42963-75
26556864   Curated Info

27

Amoroso F, et al. (2015) The P2X7 receptor is a key modulator of the PI3K/GSK3β/VEGF signaling network: evidence in experimental neuroblastoma. Oncogene 34, 5240-51
25619831   Curated Info

28

Zhou DS, et al. (2015) TACC3 promotes stemness and is a potential therapeutic target in hepatocellular carcinoma. Oncotarget 6, 24163-77
26219398   Curated Info

29

Whiting JL, et al. (2015) Protein Kinase A Opposes the Phosphorylation-dependent Recruitment of Glycogen Synthase Kinase 3β to A-kinase Anchoring Protein 220. J Biol Chem 290, 19445-57
26088133   Curated Info

30

Wiese KE, et al. (2015) Repression of SRF target genes is critical for Myc-dependent apoptosis of epithelial cells. EMBO J 34, 1554-71
25896507   Curated Info

31

Iqbal S, Howard S, LoGrasso PV (2015) Serum- and Glucocorticoid-Inducible Kinase 1 Confers Protection in Cell-Based and in In Vivo Neurotoxin Models via the c-Jun N-Terminal Kinase Signaling Pathway. Mol Cell Biol 35, 1992-2006
25825522   Curated Info

32

Palacios-Moreno J, et al. (2015) Neuroblastoma Tyrosine Kinase Signaling Networks Involve FYN and LYN in Endosomes and Lipid Rafts. PLoS Comput Biol 11, e1004130
25884760   Curated Info

33

Zhang B, et al. (2015) GSK3β-Dzip1-Rab8 Cascade Regulates Ciliogenesis after Mitosis. PLoS Biol 13, e1002129
25860027   Curated Info

34

Zhang H, et al. (2015) miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression. Oncotarget 6, 6092-104
25714029   Curated Info

35

Gao F, Al-Azayzih A, Somanath PR (2015) Discrete functions of GSK3α and GSK3β isoforms in prostate tumor growth and micrometastasis. Oncotarget 6, 5947-62
25714023   Curated Info

36

Damsky W, et al. (2015) mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation. Cancer Cell 27, 41-56
25584893   Curated Info

37

Dudiki T, et al. (2015) Changes in Carboxy Methylation and Tyrosine Phosphorylation of Protein Phosphatase PP2A Are Associated with Epididymal Sperm Maturation and Motility. PLoS One 10, e0141961
26569399   Curated Info

38

Xing HY, et al. (2015) The Cytoprotective Effect of Hyperoside against Oxidative Stress Is Mediated by the Nrf2-ARE Signaling Pathway through GSK-3β Inactivation. PLoS One 10, e0145183
26674355   Curated Info

39

Gjyshi O, et al. (2014) Kaposi's sarcoma-associated herpesvirus induces Nrf2 during de novo infection of endothelial cells to create a microenvironment conducive to infection. PLoS Pathog 10, e1004460
25340789   Curated Info

40

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

41

Watanabe T, et al. (2014) Pyrrolidinium fullerene induces apoptosis by activation of procaspase-9 via suppression of Akt in primary effusion lymphoma. Biochem Biophys Res Commun 451, 93-100
25063029   Curated Info

42

Saha A, et al. (2014) Akt phosphorylation and regulation of transketolase is a nodal point for amino Acid control of purine synthesis. Mol Cell 55, 264-76
24981175   Curated Info

43

Kao SH, et al. (2014) GSK3β controls epithelial-mesenchymal transition and tumor metastasis by CHIP-mediated degradation of Slug. Oncogene 33, 3172-82
23851495   Curated Info

44

Nicot AS, et al. (2014) Phosphorylation of NBR1 by GSK3 modulates protein aggregation. Autophagy 10, 1036-53
24879152   Curated Info

45

Mirzaa GM, et al. (2014) De novo CCND2 mutations leading to stabilization of cyclin D2 cause megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome. Nat Genet 46, 510-5
24705253   Curated Info

46

Ullal AV, et al. (2014) Cancer cell profiling by barcoding allows multiplexed protein analysis in fine-needle aspirates. Sci Transl Med 6, 219ra9
24431113   Curated Info

47

Nardi F, et al. (2014) Enhanced Insulin Sensitivity Associated with Provision of Mono and Polyunsaturated Fatty Acids in Skeletal Muscle Cells Involves Counter Modulation of PP2A. PLoS One 9, e92255
24632852   Curated Info

48

Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948
24670416   Curated Info

49

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

50

Radtke S, et al. (2013) ERK2 but not ERK1 mediates HGF-induced motility in non-small cell lung carcinoma cell lines. J Cell Sci 126, 2381-91
23549785   Curated Info

51

Luo Y, et al. (2013) PTPA activates protein phosphatase-2A through reducing its phosphorylation at tyrosine-307 with upregulation of protein tyrosine phosphatase 1B. Biochim Biophys Acta 1833, 1235-43
23428800   Curated Info

52

Sourbier C, et al. (2013) Englerin A stimulates PKCθ to inhibit insulin signaling and to simultaneously activate HSF1: pharmacologically induced synthetic lethality. Cancer Cell 23, 228-37
23352416   Curated Info

53

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

54

Chen S, et al. (2013) Tyrosine Kinase BMX Phosphorylates Phosphotyrosine-Primed Motif Mediating the Activation of Multiple Receptor Tyrosine Kinases. Sci Signal 6, ra40
23716717   Curated Info

55

DeNardo BD, et al. (2013) Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One 8, e82513
24349301   Curated Info

56

Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57
22964224   Curated Info

57

Gulen MF, et al. (2012) Inactivation of the enzyme GSK3α by the kinase IKKi promotes AKT-mTOR signaling pathway that mediates interleukin-1-induced Th17 cell maintenance. Immunity 37, 800-12
23142783   Curated Info

58

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

59

Manser C, et al. (2012) Lemur tyrosine kinase-2 signalling regulates kinesin-1 light chain-2 phosphorylation and binding of Smad2 cargo. Oncogene 31, 2773-82
21996745   Curated Info

60

Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201
22322096   Curated Info

61

Ruperez P, Gago-Martinez A, Burlingame AL, Oses-Prieto JA (2012) Quantitative phosphoproteomic analysis reveals a role for serine and threonine kinases in the cytoskeletal reorganization in early T cell receptor activation in human primary T cells. Mol Cell Proteomics 11, 171-86
22499768   Curated Info

62

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

63

Lin SY, et al. (2012) GSK3-TIP60-ULK1 signaling pathway links growth factor deprivation to autophagy. Science 336, 477-81
22539723   Curated Info

64

Mulhern D (2012) CST Curation Set: 13830; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)
Curated Info

65

Singh AM, et al. (2012) Signaling network crosstalk in human pluripotent cells: a Smad2/3-regulated switch that controls the balance between self-renewal and differentiation. Cell Stem Cell 10, 312-26
22385658   Curated Info

66

Mulhern D (2012) CST Curation Set: 13107; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

67

Mulhern D (2012) CST Curation Set: 13108; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

68

Israel MA, et al. (2012) Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 482, 216-20
22278060   Curated Info

69

Gupta M, et al. (2012) Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood 119, 476-87
22080480   Curated Info

70

Rho SB, et al. (2012) Programmed cell death 6 (PDCD6) inhibits angiogenesis through PI3K/mTOR/p70S6K pathway by interacting of VEGFR-2. Cell Signal 24, 131-9
21893193   Curated Info

71

Mulhern D (2011) CST Curation Set: 12833; Year: 2011; Biosample/Treatment: cell line, HEK 293/ku-0063794; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

72

Mulhern D (2011) CST Curation Set: 12838; Year: 2011; Biosample/Treatment: cell line, HEK 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

73

Mulhern D (2011) CST Curation Set: 12839; Year: 2011; Biosample/Treatment: cell line, HEK 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

74

Mulhern D (2011) CST Curation Set: 12840; Year: 2011; Biosample/Treatment: cell line, HEK 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

75

Mulhern D (2011) CST Curation Set: 12841; Year: 2011; Biosample/Treatment: cell line, HEK 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

76

Rikova K (2011) CST Curation Set: 13129; Year: 2011; Biosample/Treatment: cell line, MGH-7/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

77

Rikova K (2011) CST Curation Set: 13130; Year: 2011; Biosample/Treatment: cell line, MGH-8/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

78

Rikova K (2011) CST Curation Set: 13131; Year: 2011; Biosample/Treatment: cell line, MGH-9/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

79

Rikova K (2011) CST Curation Set: 13132; Year: 2011; Biosample/Treatment: cell line, MGH-10/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

80

Mulhern D (2011) CST Curation Set: 12759; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

81

Mulhern D (2011) CST Curation Set: 12760; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

82

Mulhern D (2011) CST Curation Set: 12752; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

83

Mulhern D (2011) CST Curation Set: 12753; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

84

Mulhern D (2011) CST Curation Set: 12754; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

85

Mulhern D (2011) CST Curation Set: 12755; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

86

Rapley J, Oshiro N, Ortiz-Vega S, Avruch J (2011) The mechanism of insulin-stimulated 4E-BP protein binding to mammalian target of rapamycin (mTOR) complex 1 and its contribution to mTOR complex 1 signaling. J Biol Chem 286, 38043-53
21914810   Curated Info

87

Guo JP, Coppola D, Cheng JQ (2011) IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation. J Biol Chem 286, 37389-98
21908616   Curated Info

88

Wu J, et al. (2011) HAb18G/CD147 promotes epithelial-mesenchymal transition through TGF-β signaling and is transcriptionally regulated by Slug. Oncogene 30, 4410-27
21532623   Curated Info

89

Mulhern D (2011) CST Curation Set: 12685; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

90

Mulhern D (2011) CST Curation Set: 12677; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

91

Mulhern D (2011) CST Curation Set: 12678; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

92

Mulhern D (2011) CST Curation Set: 12679; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

93

Mulhern D (2011) CST Curation Set: 12680; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

94

Mulhern D (2011) CST Curation Set: 12681; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

95

Mulhern D (2011) CST Curation Set: 12683; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

96

Chen S, et al. (2011) Celecoxib promotes c-FLIP degradation through Akt-independent inhibition of GSK3. Cancer Res 71, 6270-81
21868755   Curated Info

97

Mounir Z, et al. (2011) Akt determines cell fate through inhibition of the PERK-eIF2α phosphorylation pathway. Sci Signal 4, ra62
21954288   Curated Info

98

Guo A (2011) CST Curation Set: 12069; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

99

Guo A (2011) CST Curation Set: 12073; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

100

Guo A (2011) CST Curation Set: 12074; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

101

Yao S, et al. (2011) B7-h2 is a costimulatory ligand for CD28 in human. Immunity 34, 729-40
21530327   Curated Info

102

Neumann M, et al. (2011) Glycogen synthase kinase-3β is a crucial mediator of signal-induced RelB degradation. Oncogene 30, 2485-92
21217772   Curated Info

103

Guo A (2011) CST Curation Set: 11985; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP
Curated Info

104

Moritz A (2011) CST Curation Set: 11933; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

105

Moritz A (2011) CST Curation Set: 11937; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

106

Moritz A (2011) CST Curation Set: 11938; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

107

Moritz A (2011) CST Curation Set: 11940; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

108

Moritz A (2011) CST Curation Set: 11943; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

109

Wang H, et al. (2011) Convergence of the mammalian target of rapamycin complex 1- and glycogen synthase kinase 3-β-signaling pathways regulates the innate inflammatory response. J Immunol 186, 5217-26
21422248   Curated Info

110

Lee JE, et al. (2011) Akt/GSK3β signaling is involved in fipronil-induced apoptotic cell death of human neuroblastoma SH-SY5Y cells. Toxicol Lett 202, 133-41
21296133   Curated Info

111

Xie X, et al. (2011) IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation. Proc Natl Acad Sci U S A 108, 6474-9
21464307   Curated Info

112

Harris SJ, et al. (2011) Evidence that the lipid phosphatase SHIP-1 regulates T lymphocyte morphology and motility. J Immunol 186, 4936-45
21402888   Curated Info

113

Kennedy AL, et al. (2011) Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell 42, 36-49
21474066   Curated Info

114

Jordan SD, et al. (2011) Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. Nat Cell Biol 13, 434-46
21441927   Curated Info

115

Thayyullathil F, et al. (2011) Protein phosphatase 1-dependent dephosphorylation of Akt is the prime signaling event in sphingosine-induced apoptosis in Jurkat cells. J Cell Biochem 112, 1138-53
21308747   Curated Info

116

Murata H, et al. (2011) A new cytosolic pathway from a Parkinson disease-associated kinase, BRPK/PINK1: activation of AKT via mTORC2. J Biol Chem 286, 7182-9
21177249   Curated Info

117

Ku BM, et al. (2011) Caffeine inhibits cell proliferation and regulates PKA/GSK3β pathways in U87MG human glioma cells. Mol Cells 31, 275-9
21229324   Curated Info

118

Guo A (2011) CST Curation Set: 11299; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

119

Guo A (2011) CST Curation Set: 11302; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

120

Rooney B, et al. (2011) CTGF/CCN2 activates canonical Wnt signalling in mesangial cells through LRP6: implications for the pathogenesis of diabetic nephropathy. FEBS Lett 585, 531-8
21237163   Curated Info

121

Jensen J, et al. (2011) Effects of adrenaline on whole-body glucose metabolism and insulin-mediated regulation of glycogen synthase and PKB phosphorylation in human skeletal muscle. Metabolism 60, 215-26
20153492   Curated Info

122

Lebel M, Cyr M (2011) Molecular and cellular events of dopamine D1 receptor-mediated tau phosphorylation in SK-N-MC cells. Synapse 65, 69-76
20506302   Curated Info

123

Rikova K (2011) CST Curation Set: 11015; Year: 2011; Biosample/Treatment: cell line, NCI-H2073/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

124

Rikova K (2011) CST Curation Set: 11007; Year: 2011; Biosample/Treatment: cell line, LOU-NH91/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

125

Rikova K (2011) CST Curation Set: 11013; Year: 2011; Biosample/Treatment: cell line, NCI-H226/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

126

Rikova K (2011) CST Curation Set: 11018; Year: 2011; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

127

Rikova K (2011) CST Curation Set: 11006; Year: 2011; Biosample/Treatment: cell line, NCI-H1975/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

128

Rikova K (2011) CST Curation Set: 11016; Year: 2011; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

129

Rikova K (2011) CST Curation Set: 11009; Year: 2011; Biosample/Treatment: cell line, DV-90/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

130

Rikova K (2011) CST Curation Set: 11004; Year: 2011; Biosample/Treatment: cell line, NCI-H2342/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

131

Rikova K (2011) CST Curation Set: 11005; Year: 2011; Biosample/Treatment: cell line, Calu-3/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

132

Rikova K (2011) CST Curation Set: 11019; Year: 2011; Biosample/Treatment: cell line, NCI-H2170/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

133

Chen CH, et al. (2011) ER Stress Inhibits mTORC2 and Akt Signaling Through GSK-3{beta}-Mediated Phosphorylation of Rictor. Sci Signal 4, ra10
21343617   Curated Info

134

Yung HW, Charnock-Jones DS, Burton GJ (2011) Regulation of AKT phosphorylation at Ser473 and Thr308 by endoplasmic reticulum stress modulates substrate specificity in a severity dependent manner. PLoS One 6, e17894
21445305   Curated Info

135

Sundaresan NR, et al. (2011) The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Sci Signal 4, ra46
21775285   Curated Info

136

Wright JK, et al. (2010) HER1 Signaling Mediates Extravillous Trophoblast Differentiation in Humans. Biol Reprod 83, 1036-45
20739666   Curated Info

137

Lei CQ, et al. (2010) Glycogen synthase kinase 3β regulates IRF3 transcription factor-mediated antiviral response via activation of the kinase TBK1. Immunity 33, 878-89
21145761   Curated Info

138

Karyo R, et al. (2010) Identification of eukaryotic elongation factor-2 as a novel cellular target of lithium and glycogen synthase kinase-3. Mol Cell Neurosci 45, 449-55
20708687   Curated Info

139

Possemato A (2010) CST Curation Set: 10867; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

140

Possemato A (2010) CST Curation Set: 10869; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

141

Possemato A (2010) CST Curation Set: 10868; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

142

Possemato A (2010) CST Curation Set: 10959; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

143

Possemato A (2010) CST Curation Set: 10783; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

144

Possemato A (2010) CST Curation Set: 10790; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

145

Possemato A (2010) CST Curation Set: 10781; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

146

Possemato A (2010) CST Curation Set: 10789; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

147

Possemato A (2010) CST Curation Set: 10782; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

148

Possemato A (2010) CST Curation Set: 10787; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

149

Possemato A (2010) CST Curation Set: 10788; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

150

Possemato A (2010) CST Curation Set: 10785; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

151

Possemato A (2010) CST Curation Set: 10793; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

152

Possemato A (2010) CST Curation Set: 10786; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

153

Possemato A (2010) CST Curation Set: 10792; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

154

Possemato A (2010) CST Curation Set: 10780; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

155

Possemato A (2010) CST Curation Set: 10784; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

156

Possemato A (2010) CST Curation Set: 10838; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

157

Possemato A (2010) CST Curation Set: 10777; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

158

Possemato A (2010) CST Curation Set: 10775; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

159

Possemato A (2010) CST Curation Set: 10774; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

160

Possemato A (2010) CST Curation Set: 10778; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

161

Possemato A (2010) CST Curation Set: 10779; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

162

Possemato A (2010) CST Curation Set: 10714; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

163

Possemato A (2010) CST Curation Set: 10734; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

164

Possemato A (2010) CST Curation Set: 10726; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

165

Possemato A (2010) CST Curation Set: 10730; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

166

Possemato A (2010) CST Curation Set: 10733; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

167

Possemato A (2010) CST Curation Set: 10728; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

168

Possemato A (2010) CST Curation Set: 10731; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

169

Xiao L, et al. (2010) Protein phosphatase-1 regulates Akt1 signal transduction pathway to control gene expression, cell survival and differentiation. Cell Death Differ 17, 1448-62
20186153   Curated Info

170

Possemato A (2010) CST Curation Set: 10531; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

171

Possemato A (2010) CST Curation Set: 10157; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

172

Possemato A (2010) CST Curation Set: 10146; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

173

Possemato A (2010) CST Curation Set: 10150; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

174

Possemato A (2010) CST Curation Set: 10160; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

175

Possemato A (2010) CST Curation Set: 10161; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

176

Possemato A (2010) CST Curation Set: 10158; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

177

Possemato A (2010) CST Curation Set: 10142; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

178

Possemato A (2010) CST Curation Set: 10162; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

179

Possemato A (2010) CST Curation Set: 10143; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

180

Possemato A (2010) CST Curation Set: 10156; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

181

Possemato A (2010) CST Curation Set: 10155; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

182

Possemato A (2010) CST Curation Set: 10154; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

183

Possemato A (2010) CST Curation Set: 10159; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

184

Possemato A (2010) CST Curation Set: 10147; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

185

Possemato A (2010) CST Curation Set: 10163; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

186

Possemato A (2010) CST Curation Set: 10151; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

187

Possemato A (2010) CST Curation Set: 10122; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

188

Possemato A (2010) CST Curation Set: 10121; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

189

Possemato A (2010) CST Curation Set: 10118; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

190

Possemato A (2010) CST Curation Set: 10123; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

191

Possemato A (2010) CST Curation Set: 10125; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

192

Possemato A (2010) CST Curation Set: 10120; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

193

Beausoleil S (2010) CST Curation Set: 10285; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

194

Beausoleil S (2010) CST Curation Set: 10278; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

195

Beausoleil S (2010) CST Curation Set: 10284; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

196

Beausoleil S (2010) CST Curation Set: 10280; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

197

Beausoleil S (2010) CST Curation Set: 10279; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

198

Liu J, Agarwal S (2010) Mechanical signals activate vascular endothelial growth factor receptor-2 to upregulate endothelial cell proliferation during inflammation. J Immunol 185, 1215-21
20548028   Curated Info

199

Possemato A (2010) CST Curation Set: 10165; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

200

Possemato A (2010) CST Curation Set: 10166; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

201

Possemato A (2010) CST Curation Set: 10127; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

202

Possemato A (2010) CST Curation Set: 10126; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

203

Guo A (2010) CST Curation Set: 9944; Year: 2010; Biosample/Treatment: cell line, LAN-6/NGF; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

204

Guo A (2010) CST Curation Set: 9943; Year: 2010; Biosample/Treatment: cell line, LAN-6/untreated; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

205

Guo A (2010) CST Curation Set: 9942; Year: 2010; Biosample/Treatment: cell line, SMS-KCN-A/untreated; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

206

Guo A (2010) CST Curation Set: 9946; Year: 2010; Biosample/Treatment: cell line, SH-SY5Y/NGF; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

207

Guo A (2010) CST Curation Set: 9945; Year: 2010; Biosample/Treatment: cell line, SH-SY5Y/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

208

Dulla K, et al. (2010) Quantitative site-specific phosphorylation dynamics of human protein kinases during mitotic progression. Mol Cell Proteomics 9, 1167-81
20097925   Curated Info

209

Deng H, et al. (2010) Pulmonary artery smooth muscle hypertrophy: roles of glycogen synthase kinase-3beta and p70 ribosomal S6 kinase. Am J Physiol Lung Cell Mol Physiol 298, L793-803
20190034   Curated Info

210

Qiao M, et al. (2010) Mst1 is an interacting protein that mediates PHLPPs' induced apoptosis. Mol Cell 38, 512-23
20513427   Curated Info

211

Possemato A (2010) CST Curation Set: 9732; Year: 2010; Biosample/Treatment: cell line, H1650/Phenformin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

212

Possemato A (2010) CST Curation Set: 9629; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

213

Possemato A (2010) CST Curation Set: 9624; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

214

Possemato A (2010) CST Curation Set: 9627; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

215

Possemato A (2010) CST Curation Set: 9628; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

216

Possemato A (2010) CST Curation Set: 9630; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

217

Possemato A (2010) CST Curation Set: 9631; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

218

Possemato A (2010) CST Curation Set: 9620; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

219

Possemato A (2010) CST Curation Set: 9623; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

220

Possemato A (2010) CST Curation Set: 9621; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

221

Possemato A (2010) CST Curation Set: 9622; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

222

Possemato A (2010) CST Curation Set: 9618; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

223

Possemato A (2010) CST Curation Set: 9625; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

224

Possemato A (2010) CST Curation Set: 9626; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

225

Possemato A (2010) CST Curation Set: 9619; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

226

Goodwin CR, et al. (2010) Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation. Cancer Res 70, 2932-41
20233866   Curated Info

227

Mallon R, et al. (2010) Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor. Mol Cancer Ther 9, 976-84
20371716   Curated Info

228

Ye Y, et al. (2010) ERalpha signaling through slug regulates E-cadherin and EMT. Oncogene 29, 1451-62
20101232   Curated Info

229

Possemato A (2010) CST Curation Set: 9254; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP
Curated Info

230

Singh A, et al. (2010) Protein phosphatase 2A reactivates FOXO3a through a dynamic interplay with 14-3-3 and AKT. Mol Biol Cell 21, 1140-52
20110348   Curated Info

231

Possemato A (2010) CST Curation Set: 9068; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)XpS
Curated Info

232

Possemato A (2010) CST Curation Set: 9071; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)XpS
Curated Info

233

Chresta CM, et al. (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 70, 288-98
20028854   Curated Info

234

Yang F, et al. (2010) Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways. Mol Cancer Res 8, 35-45
20053726   Curated Info

235

Terracciano C, Nogalska A, Engel WK, Askanas V (2010) In AbetaPP-overexpressing cultured human muscle fibers proteasome inhibition enhances phosphorylation of AbetaPP751 and GSK3beta activation: effects mitigated by lithium and apparently relevant to sporadic inclusion-body myositis. J Neurochem 112, 389-96
19878439   Curated Info

236

Banerjee Mustafi S, Chakraborty PK, Raha S (2010) Modulation of Akt and ERK1/2 pathways by resveratrol in chronic myelogenous leukemia (CML) cells results in the downregulation of Hsp70. PLoS One 5, e8719
20090934   Curated Info

237

Chung R, et al. (2010) Biological and clinical significance of GSK-3beta in mantle cell lymphoma--an immunohistochemical study. Int J Clin Exp Pathol 3, 244-53
20224723   Curated Info

238

Moritz A, et al. (2010) Akt-RSK-S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases. Sci Signal 3, ra64
20736484   Curated Info

239

Mishra P, Senthivinayagam S, Rana A, Rana B (2010) Glycogen Synthase Kinase-3beta regulates Snail and beta-catenin during gastrin-induced migration of gastric cancer cells. J Mol Signal 5, 9
20637111   Curated Info

240

De Toni-Costes F, et al. (2010) A New alpha5beta1 integrin-dependent survival pathway through GSK3beta activation in leukemic cells. PLoS One 5, e9807
20352103   Curated Info

241

Gu M, et al. (2009) Inositol hexaphosphate suppresses growth and induces apoptosis in prostate carcinoma cells in culture and nude mouse xenograft: PI3K-Akt pathway as potential target. Cancer Res 69, 9465-72
19920184   Curated Info

242

Davies MA, et al. (2009) Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res 15, 7538-7546
19996208   Curated Info

243

Haughian JM, Reno EM, Thorne AM, Bradford AP (2009) Protein kinase C alpha-dependent signaling mediates endometrial cancer cell growth and tumorigenesis. Int J Cancer 125, 2556-64
19672862   Curated Info

244

Li X, Liu J, Gao T (2009) beta-TrCP-mediated ubiquitination and degradation of PHLPP1 are negatively regulated by Akt. Mol Cell Biol 29, 6192-205
19797085   Curated Info

245

Zhang YW, et al. (2009) A functional mouse retroposed gene Rps23r1 reduces Alzheimer's beta-amyloid levels and tau phosphorylation. Neuron 64, 328-40
19914182   Curated Info

246

Dong W, Albers JJ, Vuletic S (2009) Phospholipid transfer protein reduces phosphorylation of tau in human neuronal cells. J Neurosci Res 87, 3176-85
19472218   Curated Info

247

Wang Z, et al. (2009) Dependence of EGF-induced increases in corneal epithelial proliferation and migration on GSK-3 inactivation. Invest Ophthalmol Vis Sci 50, 4828-35
19443725   Curated Info

248

Zhou J (2009) CST Curation Set: 7640; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

249

Zhou J (2009) CST Curation Set: 7643; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

250

Zhou J (2009) CST Curation Set: 7644; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

251

Zhou J (2009) CST Curation Set: 7641; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

252

Zhou J (2009) CST Curation Set: 7642; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

253

Zhou J (2009) CST Curation Set: 7639; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

254

Zhong D, et al. (2009) The Glycolytic Inhibitor 2-Deoxyglucose Activates Multiple Prosurvival Pathways through IGF1R. J Biol Chem 284, 23225-33
19574224   Curated Info

255

Possemato A (2009) CST Curation Set: 7415; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

256

Possemato A (2009) CST Curation Set: 7416; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

257

Possemato A (2009) CST Curation Set: 7407; Year: 2009; Biosample/Treatment: cell line, HepG2/untreated; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

258

Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64
19369195   Curated Info

259

Possemato A (2009) CST Curation Set: 7267; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

260

Possemato A (2009) CST Curation Set: 7268; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

261

Possemato A (2009) CST Curation Set: 7263; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

262

Possemato A (2009) CST Curation Set: 7261; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

263

Possemato A (2009) CST Curation Set: 7259; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

264

Possemato A (2009) CST Curation Set: 7262; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

265

Possemato A (2009) CST Curation Set: 7264; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

266

Ren H (2009) CST Curation Set: 7180; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

267

Zhou J (2009) CST Curation Set: 7214; Year: 2009; Biosample/Treatment: cell line, LNCaP/untreated; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

268

Chiang MH, et al. (2009) Mechanism of Hypoxia-induced GCM1 Degradation: IMPLICATIONS FOR THE PATHOGENESIS OF PREECLAMPSIA. J Biol Chem 284, 17411-9
19416964   Curated Info

269

Possemato A (2009) CST Curation Set: 6913; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

270

Possemato A (2009) CST Curation Set: 6914; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

271

Possemato A (2009) CST Curation Set: 6915; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

272

Possemato A (2009) CST Curation Set: 6908; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

273

Possemato A (2009) CST Curation Set: 6909; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

274

Possemato A (2009) CST Curation Set: 6910; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

275

Possemato A (2009) CST Curation Set: 6911; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

276

Possemato A (2009) CST Curation Set: 6912; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

277

Possemato A (2009) CST Curation Set: 6904; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

278

Li Y (2009) CST Curation Set: 6879; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

279

Possemato A (2009) CST Curation Set: 6905; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

280

Possemato A (2009) CST Curation Set: 6906; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

281

Possemato A (2009) CST Curation Set: 6907; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

282

Possemato A (2009) CST Curation Set: 6902; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

283

Possemato A (2009) CST Curation Set: 6903; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

284

Possemato A (2009) CST Curation Set: 6901; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

285

Possemato A (2009) CST Curation Set: 6900; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

286

Possemato A (2009) CST Curation Set: 6898; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

287

Possemato A (2009) CST Curation Set: 6899; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

288

Possemato A (2009) CST Curation Set: 6896; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

289

Possemato A (2009) CST Curation Set: 6897; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

290

Old WM, et al. (2009) Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell 34, 115-31
19362540   Curated Info

291

Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8
19276368   Curated Info

292

Ryu D, et al. (2009) TORC2 regulates hepatic insulin signaling via a mammalian phosphatidic acid phosphatase, LIPIN1. Cell Metab 9, 240-51
19254569   Curated Info

293

Farnsworth C (2009) CST Curation Set: 6186; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985
Curated Info

294

Zong H, et al. (2009) Insulin resistance in striated muscle-specific integrin receptor beta1-deficient mice. J Biol Chem 284, 4679-88
19064993   Curated Info

295

Dar AA, Belkhiri A, El-Rifai W (2009) The aurora kinase A regulates GSK-3beta in gastric cancer cells. Oncogene 28, 866-75
19060929   Curated Info

296

Zhou J (2009) CST Curation Set: 6052; Year: 2009; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

297

Zhou J (2009) CST Curation Set: 6054; Year: 2009; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

298

Zhou J (2009) CST Curation Set: 6053; Year: 2009; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

299

Zhou J (2009) CST Curation Set: 6049; Year: 2009; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

300

Zhou J (2009) CST Curation Set: 6050; Year: 2009; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

301

Zhou J (2009) CST Curation Set: 6048; Year: 2009; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

302

Zhou J (2009) CST Curation Set: 6051; Year: 2009; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

303

Zhou J (2009) CST Curation Set: 6047; Year: 2009; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

304

Nemoto T, Yanagita T, Kanai T, Wada A (2009) Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: the role of GSK-3beta in the maintenance of steady-state levels of insulin receptor signaling molecules and Na(v)1.7 sodium channel in adrenal chromaffin cells. J Pharmacol Sci 109, 157-61
19179806   Curated Info

305

Moritz A (2009) CST Curation Set: 5890; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/rapamycin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

306

Moritz A (2009) CST Curation Set: 5891; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/rapamycin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

307

Moritz A (2009) CST Curation Set: 5893; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/U 0126; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

308

Moritz A (2009) CST Curation Set: 5894; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/U 0126; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

309

Moritz A (2009) CST Curation Set: 5888; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/wortmannin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

310

Moritz A (2009) CST Curation Set: 5884; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

311

Moritz A (2009) CST Curation Set: 5885; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

312

Moritz A (2009) CST Curation Set: 5887; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/wortmannin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

313

Yang XV, et al. (2009) Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. Proc Natl Acad Sci U S A 106, 274-9
19116273   Curated Info

314

Wu Y, Evers BM, Zhou BP (2009) Small C-terminal Domain Phosphatase Enhances Snail Activity through Dephosphorylation. J Biol Chem 284, 640-8
19004823   Curated Info

315

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

316

Chua BT, et al. (2009) Regulation of Akt(ser473) phosphorylation by Choline kinase in breast carcinoma cells. Mol Cancer 8, 131
20042122   Curated Info

317

Monje PV, Athauda G, Wood PM (2008) Protein kinase A-mediated gating of neuregulin-dependent ErbB2-ErbB3 activation underlies the synergistic action of cAMP on Schwann cell proliferation. J Biol Chem 283, 34087-100
18799465   Curated Info

318

Koomoa DL, et al. (2008) Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma. Cancer Res 68, 9825-31
19047162   Curated Info

319

Spalding AC, et al. (2008) Enzastaurin, an inhibitor of PKCbeta, Enhances Antiangiogenic Effects and Cytotoxicity of Radiation against Endothelial Cells. Transl Oncol 1, 195-201
19043530   Curated Info

320

Moritz A (2008) CST Curation Set: 5660; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/U 0126; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

321

Moritz A (2008) CST Curation Set: 5659; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/U 0126; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

322

Moritz A (2008) CST Curation Set: 5650; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/rapamycin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

323

Moritz A (2008) CST Curation Set: 5651; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/rapamycin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

324

Moritz A (2008) CST Curation Set: 5653; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

325

Moritz A (2008) CST Curation Set: 5654; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

326

Moritz A (2008) CST Curation Set: 5656; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/wortmannin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

327

Moritz A (2008) CST Curation Set: 5657; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/wortmannin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

328

Ouchi N, et al. (2008) Follistatin-like 1, a secreted muscle protein, promotes endothelial cell function and revascularization in ischemic tissue through a nitric-oxide synthase-dependent mechanism. J Biol Chem 283, 32802-11
18718903   Curated Info

329

Moritz A (2008) CST Curation Set: 5443; Year: 2008; Biosample/Treatment: cell line, NCI-H1703/U 0126; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

330

Moritz A (2008) CST Curation Set: 5444; Year: 2008; Biosample/Treatment: cell line, NCI-H1703/U 0126; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

331

Moritz A (2008) CST Curation Set: 5446; Year: 2008; Biosample/Treatment: cell line, NCI-H1703/wortmannin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

332

Moritz A (2008) CST Curation Set: 5447; Year: 2008; Biosample/Treatment: cell line, NCI-H1703/wortmannin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

333

Moritz A (2008) CST Curation Set: 5376; Year: 2008; Biosample/Treatment: cell line, MKN-45/U 0126; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

334

Moritz A (2008) CST Curation Set: 5377; Year: 2008; Biosample/Treatment: cell line, MKN-45/U 0126; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

335

Moritz A (2008) CST Curation Set: 5379; Year: 2008; Biosample/Treatment: cell line, MKN-45/wortmannin; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

336

Moritz A (2008) CST Curation Set: 5382; Year: 2008; Biosample/Treatment: cell line, MKN-45/rapamycin; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

337

Moritz A (2008) CST Curation Set: 5383; Year: 2008; Biosample/Treatment: cell line, MKN-45/rapamycin; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

338

Zhong D, et al. (2008) LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins. Cancer Res 68, 7270-7
18794113   Curated Info

339

Venè R, et al. (2008) Glycogen synthase kinase 3beta regulates cell death induced by synthetic triterpenoids. Cancer Res 68, 6987-96
18757413   Curated Info

340

Greenhaff PL, et al. (2008) Disassociation between the effects of amino acids and insulin on signaling, ubiquitin ligases, and protein turnover in human muscle. Am J Physiol Endocrinol Metab 295, E595-604
18577697   Curated Info

341

Moritz A (2008) CST Curation Set: 5009; Year: 2008; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

342

Moritz A (2008) CST Curation Set: 5010; Year: 2008; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

343

Moritz A (2008) CST Curation Set: 5013; Year: 2008; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

344

Moritz A (2008) CST Curation Set: 5014; Year: 2008; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

345

Kotliarova S, et al. (2008) Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res 68, 6643-51
18701488   Curated Info

346

Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48
18691976   Curated Info

347

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

348

Austin RL, et al. (2008) siRNA-mediated reduction of inhibitor of nuclear factor-kappaB kinase prevents tumor necrosis factor-alpha-induced insulin resistance in human skeletal muscle. Diabetes 57, 2066-73
18443205   Curated Info

349

Pai R, et al. (2008) Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling. Cancer Res 68, 5086-95
18593907   Curated Info

350

Lee JY, et al. (2008) Mel-18 negatively regulates INK4a/ARF-independent cell cycle progression via Akt inactivation in breast cancer. Cancer Res 68, 4201-9